348 related articles for article (PubMed ID: 27771636)
21. Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective.
Ramirez Gonzalez A; Farrell M; Menning L; Garon J; Everts H; Hampton LM; Dolan SB; Shendale S; Wanyoike S; Veira CL; Châtellier GMD; Kurji F; Rubin J; Boualam L; Chang Blanc D; Patel M
J Infect Dis; 2017 Jul; 216(suppl_1):S183-S192. PubMed ID: 28838179
[TBL] [Abstract][Full Text] [Related]
22. The global polio eradication initiative: lessons learned and prospects for success.
Aylward B; Tangermann R
Vaccine; 2011 Dec; 29 Suppl 4():D80-5. PubMed ID: 22486981
[TBL] [Abstract][Full Text] [Related]
23. Breaking the Last Chains of Poliovirus Transmission: Progress and Challenges in Global Polio Eradication.
Kew O; Pallansch M
Annu Rev Virol; 2018 Sep; 5(1):427-451. PubMed ID: 30001183
[TBL] [Abstract][Full Text] [Related]
24. Lessons Learned From Managing the Planning and Implementation of Inactivated Polio Vaccine Introduction in Support of the Polio Endgame.
Zipursky S; Patel M; Farrell M; Gonzalez AR; Kachra T; Folly Y; Kurji F; Veira CL; Wootton E; Hampton LM
J Infect Dis; 2017 Jul; 216(suppl_1):S15-S23. PubMed ID: 28838203
[TBL] [Abstract][Full Text] [Related]
25. Potential Future Use, Costs, and Value of Poliovirus Vaccines.
Thompson KM; Kalkowska DA
Risk Anal; 2021 Feb; 41(2):349-363. PubMed ID: 32645244
[TBL] [Abstract][Full Text] [Related]
26. Introduction of Inactivated Poliovirus Vaccine and Trivalent Oral Polio Vaccine/Bivalent Oral Polio Vaccine Switch in the African Region.
Tevi-Benissan C; Okeibunor J; du Châtellier GM; Assefa A; Biey JN; Cheikh D; Eshetu M; Anya BP; Dao H; Nasir Y; Akanmori BD; Mihigo R
J Infect Dis; 2017 Jul; 216(suppl_1):S66-S75. PubMed ID: 28838178
[TBL] [Abstract][Full Text] [Related]
27. Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029.
Kalkowska DA; Thompson KM
Risk Anal; 2021 Feb; 41(2):364-375. PubMed ID: 33590519
[TBL] [Abstract][Full Text] [Related]
28. Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication.
Modlin JF; Bandyopadhyay AS; Sutter R
J Infect Dis; 2021 Sep; 224(12 Suppl 2):S398-S404. PubMed ID: 34590135
[TBL] [Abstract][Full Text] [Related]
29. Introduction of inactivated poliovirus vaccine leading into the polio eradication endgame strategic plan; Hangzhou, China, 2010-2014.
Liu Y; Wang J; Liu S; Du J; Wang L; Gu W; Xu Y; Zuo S; Xu E; An Z
Vaccine; 2017 Mar; 35(9):1281-1286. PubMed ID: 28161421
[TBL] [Abstract][Full Text] [Related]
30. The polio endgame: rationale behind the change in immunisation.
Garon J; Patel M
Arch Dis Child; 2017 Apr; 102(4):362-365. PubMed ID: 28096107
[TBL] [Abstract][Full Text] [Related]
31. [Polio close to eradication].
Norrby E; Uhnoo I; Brytting M; Zakikhany K; Lepp T; Olin P
Lakartidningen; 2017 Sep; 114():. PubMed ID: 28926080
[TBL] [Abstract][Full Text] [Related]
32. The Need and Potential of Inactivated Poliovirus Vaccine.
Garon J; Orenstein W; John TJ
Indian Pediatr; 2016 Aug; 53 Suppl 1():S2-S6. PubMed ID: 27771632
[TBL] [Abstract][Full Text] [Related]
33. Progress Toward Polio Eradication - Worldwide, January 2020-April 2022.
Rachlin A; Patel JC; Burns CC; Jorba J; Tallis G; O'Leary A; Wassilak SGF; Vertefeuille JF
MMWR Morb Mortal Wkly Rep; 2022 May; 71(19):650-655. PubMed ID: 35552352
[TBL] [Abstract][Full Text] [Related]
34. Global Polio Eradication Initiative Strategic Plan, 2004.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2004 Feb; 53(5):107-8. PubMed ID: 14961005
[TBL] [Abstract][Full Text] [Related]
35. Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036.
Thompson KM; Kalkowska DA; Badizadegan K
Expert Rev Vaccines; 2022 Nov; 21(11):1667-1674. PubMed ID: 36154436
[TBL] [Abstract][Full Text] [Related]
36. Intensified Local Resource Mobilization for the Polio Eradication Initiative: The Experience of World Health Organization in Nigeria During 2008-2015.
Yehualashet YG; Horton J; Mkanda P; Vaz RG; Afolabi O; Gashu SG; Banda R; O'Malley H; Nsubuga P
J Infect Dis; 2016 May; 213 Suppl 3(Suppl 3):S101-7. PubMed ID: 26912380
[TBL] [Abstract][Full Text] [Related]
37. Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame.
Kalkowska DA; Pallansch MA; Wassilak SGF; Cochi SL; Thompson KM
Risk Anal; 2021 Feb; 41(2):248-265. PubMed ID: 31960533
[TBL] [Abstract][Full Text] [Related]
38. The new polio eradication end game: rationale and supporting evidence.
Sutter RW; Platt L; Mach O; Jafari H; Aylward RB
J Infect Dis; 2014 Nov; 210 Suppl 1():S434-8. PubMed ID: 25316865
[TBL] [Abstract][Full Text] [Related]
39. Polio endgame: the global switch from tOPV to bOPV.
Garon J; Seib K; Orenstein WA; Ramirez Gonzalez A; Chang Blanc D; Zaffran M; Patel M
Expert Rev Vaccines; 2016 Jun; 15(6):693-708. PubMed ID: 26751187
[TBL] [Abstract][Full Text] [Related]
40. Experience With Inactivated Polio Vaccine Introduction and the "Switch" From Trivalent to Bivalent Oral Polio Vaccine in the World Health Organization's Western Pacific Region.
Gurung S; Harris JB; Eltayeb AO; Hampton LM; Diorditsa S; Avagyan T; Schluter WW
J Infect Dis; 2017 Jul; 216(suppl_1):S101-S108. PubMed ID: 28838170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
